Digest. Absorb. Nourish.

Patients living with serious medical conditions due to rare diseases often require enteral feeding for nutrition. Many of these patients struggle with digesting fat, essential for growth, immunity, and organ function. Unable to get the full nutritional benefits from enteral formula, these patients may experience poor outcomes and significant health consequences as a result.

Alcresta develops rare disease, enzyme-based products helping to address fat malabsorption (often due to exocrine pancreatic insufficiency) in patients who are enterally fed at home or in the hospital. Our RELiZORB® cartridge contains iLipase®, a  patented microbead/enzyme technology that breaks down fat for easy ingestion and optimal absorption.

Our Science

RELiZORB cartridge

The first and only enzyme product for use in enteral feeding. RELiZORB is a digestive enzyme cartridge designed to mimic the function of pancreatic lipase. RELiZORB helps children and adults on enteral tube feeding who have trouble breaking down and absorbing fats due to cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, and other rare diseases.


RELiZORB clinical trial now enrolling patients

Alcresta Therapeutics is actively enrolling patients for a 90 day, phase 3, open labeled exploratory study of RELiZORB. Learn more about the clinical trial by visiting ClinicalTrials.gov, trial NCT03530852.